1-1 of 1
Daniel Kalbermatten
Close
Sort by
Journal Articles

Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations

Clinical Trials & Observations Brief Report
Thierry M. Nordmann, Freimut D. Juengling, Mike Recher, Christoph T. Berger, Daniel Kalbermatten, Andreas Wicki, Aino Paasinen-Sohns, Gieri Cathomas, Alexandar Tzankov, Thomas Daikeler
Journal: Blood
Blood (2017) 129 (7): 879–882.
https://doi.org/10.1182/blood-2016-09-740217
Published: 2017